Results 11 to 20 of about 13,225 (269)

Mammary analogue secretory carcinoma in minor salivary gland [PDF]

open access: yesEinstein (São Paulo), 2022
Mammary analogue secretory carcinoma is a rare neoplasm usually confused with other neoplasms in the salivary glands region. It has great similarity with the breast carcinoma.
Lucas Moreno Ponso   +4 more
doaj   +1 more source

Biopsied non-dental plaque-induced gingival diseases in a Chinese population: a single-institute retrospective study

open access: yesBMC Oral Health, 2021
Background While inflammatory diseases such as gingivitis and periodontitis induced by dental plaque biofilms constitute the majority of gingival lesions, gingiva can also be affected by a variety of diseases with aetiologies different from bacterial ...
Xiaotian Li   +3 more
doaj   +1 more source

Management of gingival pigmentation using laser depigmentation technique

open access: yesJournal of Primary Care Dentistry and Oral Health, 2021
Gingival hyperpigmentation can be defined as a darker gingival color beyond what is normally expected. Several by-products of the physiological process such as melanin, oxyhemoglobin, carotene, reduced hemoglobin, and iron and/or pathological diseases ...
Dhirendra Kumar Singh, Arnab Mandal
doaj   +1 more source

Benign and Malignant Neoplasms Affecting Periodontal Tissues: A Retrospective Study

open access: yesEuropean Annals of Dental Sciences, 2022
Introduction: Oral neoplasms are the second most common oral lesions after reactive proliferative lesions. The aim of this study is to determine the distribution of the oral neoplasms by gender and age, and briefly discussed the clinical manifestations ...
Ömer Günhan   +4 more
doaj   +1 more source

The “Epulis” Dilemma. Considerations from Provisional to Final Diagnosis. A Systematic Review

open access: yesOral, 2021
“Epulis” is a widely used term to describe a localized gingival enlargement. However, a wide range of neoformations might present as localized, slow-growing, asymptomatic gingival masses.
Paola Costa   +4 more
doaj   +1 more source

Gingival manifestation of a therapy-related acute myelomonocytic leukemia in a patient with previously treated with R–CHOP scheme for diffuse large B-cell lymphoma

open access: yesOral and Maxillofacial Surgery Cases, 2020
Standard chemotherapy treatment for Diffuse large B-cell lymphoma (DLBCL), including cyclophosphamide, doxorubicin, vincristine and prednisone, in association with rituximab (CHOP-R) are considered associated to the development of secondary tumors.
Iacopo Panarese   +6 more
doaj   +1 more source

Cytotoxic Tumour-Selective 1,5-Diaryl-3-Oxo-1,4-Pentadienes Mounted on a Piperidine Ring

open access: yesMedicines, 2021
A series of 3,5-bis(benzylidene)-4-piperidones 2a–u were prepared as candidate cytotoxic agents. In general, the compounds are highly toxic to human gingival carcinoma (Ca9-22), human squamous carcinoma-2 (HSC-2) and human squamous carcinoma-4 (HSC-4 ...
Praveen K. Roayapalley   +11 more
doaj   +1 more source

Distribution of biopsied non plaque-induced gingival lesions in a Chilean population according to the classification of periodontal diseases

open access: yesBMC Oral Health, 2018
Background Many gingival lesions are not induced by plaque. The aim of this study was to analyze the frequency of biopsied non-plaque-induced gingival lesions (NPIGL) in a Chilean population. Methods One thousand twelve cases of biopsied gingival lesions
Patricia Hernández-Ríos   +5 more
doaj   +1 more source

Oral Manifestations in Acute Leukemia as the First Sign; The Interdisciplinary Approach of Diagnosis and Treatment [PDF]

open access: yes, 2015
Systemic diseases often present associated oral signs and symptoms, which can occur either from the beginning of the disease or during its evolution. In some cases the oral manifestations reveal an undetected and severe disease, like leukemia.
Anca, Dumitriu   +2 more
core   +3 more sources

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

open access: yesHepatology, EarlyView., 2022
Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy